Amaya Lujambio Goizueta, PhD
- ASSOCIATE PROFESSOR | Oncological Sciences
- ASSOCIATE PROFESSOR | Medicine
Research Topics:
Cancer, Epigenetics, Liver, Molecular BiologyAmaia Lujambio, PhD, is Assistant Professor, Oncological Sciences, a member of The Tisch Cancer Institute, and a member of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. Her research is focused on understanding the mechanisms of liver cancer initiation and liver cancer maintenance. Using a sophisticated precision mouse model of cancer, Dr. Lujambio is investigating biomarker-guided, precision therapies for hepatocellular carcinoma (HCC), the most common type of liver cancer. Her laboratory is also interested in the use of functional genomics for the identification of novel therapies and immunotherapies. Dr. Lujambio is the recipient of numerous honors and awards, including the Damon Runyan-Rachleff Innovation Award, NCI R37 Merit Award for Early State Investigators, and the GE Liver Junior Scientist Award.
Dr. Lujambio is on Twitter at @AmaiaLujambio
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]Education
PhD, Spanish National Cancer Center (CNIO)
Postdoc, Cold Spring Harbor Laboratory (CSHL)
Postdoc, Memorial Sloan Kettering Cancer Center
-
2015
AASLD Pinnacle Research Award in Liver Diseases -
2010
EMBO Long Term Fellowship -
2010
Ph.D. Thesis Award -
2008
EMBO Short Term Fellowship -
2007
Eduardo Gallego Award -
2006
FPU Fellowship
Liver Cancer Biology
Amaia Lujambio´s research group studies mechanisms of liver cancer initiation and liver cancer maintenance. In particular, we are interested in how genetic alterations in cancer cells contribute to tumorigenesis, alter treatment response, and create vulnerabilities that may be targeted therapeutically. Furthermore, we are also interested in understanding the role of cellular senescence in liver cancer initiation. Our research interests involve the establishment of in vitro and in vivo systems for the study of liver cancer as well as the rational use of shRNA libraries to identify drug targets for the disease. We utilize sophisticated mouse models of cancer, RNAi technology, valuable human cancer samples, and genetic and epigenetic profiling as key tools. The ultimate goal is to improve our understanding of liver cancer biology and to identify novel strategies that can be exploited therapeutically.
Visit theLujambio Laboratory
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Lujambio Goizueta during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Department of Defense (DoD); La Caixa; Memorial Sloan-Kettering Cancer Center (MSKCC); National Cancer Institute (NCI); University of Pittsburgh; agence nationale de la recherche; mineco
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.
- Clinic barcelona; University of Pennsylvania; Young Investigator Live
Royalty Payments:
- Algen
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.